EyePoint Pharmaceuticals (NASDAQ:EYPT) Rating Increased to Sell at StockNews.com
StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) to a sell rating in a research note published on Friday. Other equities analysts have also issued reports about the stock. Chardan Capital reiterated a “buy” rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. […]
StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) to a sell rating in a research note published on Friday. Other equities analysts have also issued reports about the stock. Chardan Capital reiterated a “buy” rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. […]
-logo-1200x675.png?v=20230216141636&w=240&h=240&zc=2){kind=logo}
